Compound ID | 251
Class: DNA synthesis inhibitor
| Agent Type: | Natural product; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | DNA synthesis inhibitor. Bacterial topoisomerase inhibitor |
| Target Pathogen: | Active against Staphylococcus aureus, and Clostridium difficile |
| Propensity to select resistant mutants: | Yes |
| Description: | Natural product from Kibdelosporangium sp. |
| Institute where first reported: | Merck Research Laboratories, USA |
| Year first mentioned: | 2011 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/71463014 |
| Guide to Pharmacology: | kibdelomycin A |
| Citations: |
|